Skip to search formSkip to main contentSkip to account menu

preladenant

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
The Role and Development of the Antagonist of Adenosine A2A in Parkinson’s Disease
Adenosine is a neuromodulator that regulates the body’s response to dopamine and another neurotransmitter in the brain that is… 
2014
2014
An in vivo positron emission tomography study of adenosine 2A receptor occupancy by preladenant using 11C-SCH442416 in healthy hubjects.
Background: This PET study was conducted to investigate the receptor occupancy of 11C-SCH442416 in the human brain and to… 
2013
2013
Preladenant, a selective adenosine A2A receptor antagonist, is not associated with QT/QTc prolongation
Preladenant is an orally administered adenosine2A (A2A) receptor antagonist in phase III development for Parkinson’s disease… 
2011
2011
Does Adjunctive Preladenant Reduce “Off” Time in Parkinson Disease?
Effective treatment of motor symptoms in patients with Parkinson disease becomes more difficult with disease progression, and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)